We’re all unique
So is Aummune

The future of personalized therapy for cancer
Aummune develops a first-of-its-kind individual drug-customization platform that utilizes a unique efficacy-driven selection process to match and produce a patient-specific
tri-functional aptamer drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses

Aptamers

customizable molecules for various applications
APTAMERS are structured single-stranded DNA oligonucleotides, that can be manufactured to recognize and bind any desired molecular target with high affinity and specificity.

Additionally, Aptamers exhibit several key advantages

Shorter
generation time

Lower costs of
manufacturing

Minimal batch-to-batch
variability

Higher modifiability

Thermal stability

Individually tailored tri-functional aptamers

Synergistic tumoricidal and immune effects

Constant Strand

Engages immune effector T
cells, leading to
tumor cell lysis.

Bridge

A CpG-rich domain that both fuses
the two strands and induces Antigen
Presenting Cells stimulation through
Toll-Like Receptor 9

Variable Strand

A tumor-targeting arm, selected for its
ability to bind the patient’s cancer cells
and induce cancer cell death while
avoiding effects on healthy tissue.

Tailoring the
variable strand
to every patient

Aummune’s platform utilizes a positive
and negative selection process on a
patient’s tumor and healthy cell samples,
to achieve a tumoricidal yet safe effect

Sample
processing

Efficacy-driven
selection

Personal
drug
assembly

Administration

Aummune’s unique therapeutic edge

Multi-faceted
approach to treat
solid tumors

Pretreatment
validated efficacy

No wasted effort
on ineffective
treatments

Broad spectrum
of cancer
indications

Development status

Aummune lead program, AM003, has demonstrated efficacy and safety in several animal models and, upon completion of its preclinical program and positive interactions with regulatory authorities, will start a Phase 1 clinical study in the first half of 2022.
The First-in –Human study will enroll patients with locally advanced and metastatic solid tumors.

Leadership team

Let's Connect

Tel Aviv Medical Center (TAMC),
Sammy Ofer Building, Floor 10
Weizmann St 6, Tel Aviv-Yafo, ISRAEL
info@aummune.tech